UK markets closed

Galecto, Inc. (GLTO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.78000.0000 (0.00%)
At close: 04:00PM EDT
0.8199 +0.04 (+5.12%)
After hours: 07:13PM EDT

Galecto, Inc.

Ole Maaloes Vej 3
Copenhagen N
Copenhagen 2200
Denmark
45 70 70 52 10
https://galecto.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees13

Key executives

NameTitlePayExercisedYear born
Dr. Hans T. Schambye M.D., Ph.D.Co-Founder, President, CEO & Director700.13kN/A1966
Mr. Jonathan P. Freve CPA, CPAChief Financial Officer604.93kN/A1978
Mr. Ulf J. NilssonCo-FounderN/AN/AN/A
Dr. Hakon LefflerCo-FounderN/AN/AN/A
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.Co-FounderN/AN/AN/A
Mr. Garrett Winslow Esq.Senior VP, General Counsel & Corporate SecretaryN/AN/A1979
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Corporate governance

Galecto, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.